Treatment News : Preliminary Results Suggest Good Safety and Adherence Profile for PrEP - by David Evans

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 19, 2010

Preliminary Results Suggest Good Safety and Adherence Profile for PrEP

by David Evans

People taking either daily or intermittent pre-exposure prophylaxis (PrEP) to prevent HIV infection had few side effects and relatively good adherence to these regimens, according to data presented Monday, July 19, at the XVIII International AIDS Conference (IAC) being held July 18 to 23 in Vienna.

Experts hold great hope for PrEP as an HIV prevention strategy. Currently a number of PrEP trials are ongoing, testing either Viread (tenofovir) or Truvada (tenofovir plus emtricitabine) in a variety of dosing strategies. Basic safety and adherence data are now beginning to roll in, with efficacy data expected by the end of 2010.

At the IAC, researchers in Kenya and the United States offered preliminary results from a trial that is comparing either daily Truvada PrEP or intermittent Truvada PrEP with a placebo. PrEP is being studies in three risk-groups: men who have sex with men (MSM), female sex workers (FSW) and in HIV-negative heterosexuals with an HIV-positive partner (serodiscordant couples). Thus far, early data are available on 67 MSM, 5 FSW and 32 serodiscordant couples.

Those taking either Truvada or a placebo intermittently were asked to take their study drugs on Mondays and Fridays and within two hours after having insertive sex. Adherence was measured using both self-reporting and an electronic memory cap monitor on pill bottles.

Based on these preliminary data, both PrEP strategies appear to be safe and well tolerated. All side effects reported so far have been classified as mild to moderate, and nearly all were judged by researchers as not likely related to Truvada. There have also been no cases of kidney problems, which can occur with Truvada.

Adherence was very good with daily PrEP use, and moderately good with intermittent use. Adherence rates among daily PrEP users was 84 percent among MSM and FSWs, and 100 percent among the HIV-negative partner in serodiscordant couples. Rates in those taking PrEP intermittently varied, depending on the dose. Among MSM and FSWs, 66 percent took their Monday and Friday doses correctly, but only 25 percent were able to take their post-sex dose. In the serodiscordant couples, the Monday and Friday doses were taken correctly 91 percent of the time, but the post-sex dose was taken correctly only 50 percent of the time. This is concerning, as monkey studies have revealed that the post-sex dose in intermittent strategies is very important in preventing transmission.

The number of people included in this analysis is quite small, and the data are preliminary, so it isn’t yet possible to draw firm conclusions. Nevertheless, the authors conclude that, “These preliminary, blinded data suggest that intermittent and daily [Truvada] have similarly acceptable safety profiles.”

“Adherence to fixed doses was comparable to daily dosing,” they continue. “However, post-coital dosing may be challenging in these settings.”

Search: PrEP, Viread, tenofovir, Truvada, emtricitabine, Kenya, intermittent


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    fokisi
    Long Beach
    California


    Loveladyd
    Washington
    DC


    jimmy807
    San Antonio
    Texas


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.